Author name: DrugPatentWatch

Top-Level Key Takeaways 1. What the Rule of Three Actually Is (and What It Isn’t) 1.1 The Economic Premise The […]

1. Why the Generic Market Runs on Partnerships, Not Margins Generics and biosimilars filled 90% of all U.S. prescriptions dispensed

Executive Framing: The Cost Problem That Waste Built {#executive-framing} Generic drugs fill roughly nine out of every ten prescriptions dispensed

Section 1: The Modern API Manufacturing Landscape 1.1 What an API Is, and Why Its Manufacturing Process Is a Core

I. Executive Summary Key Takeaways The global CDMO market is on track to reach $465 billion by 2032, driven by

Generic drugs account for roughly 91% of all U.S. prescriptions filled while representing only about 18% of total drug spend.

A deep-dive reference for pharma/biotech IP teams, R&D leads, and institutional investors operating in or sourcing from the European market.

1. The Market Structure Forcing Manufacturing Innovation The global generic drug market generated approximately $245 billion in 2020 and is

1. The Strategic Stakes: Why Your CDMO Model Choice Determines IP Value, Not Just Cost The question most pharmaceutical executives